Title

Description description description. Description description description. Description description description.

Switching to TASIGNA

Making the switch.

There are a number of reasons why your doctor may decide it is time for you to switch from another medication to TASIGNA® (nilotinib) capsules to treat Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP):

  • Lack of response: Your body does not respond to treatment
  • Drug resistance: Over time, you lose your response to your medication. Your doctor may refer to this as drug resistance
  • Drug intolerance: Your side effects become so bothersome they may keep you from taking your medication. Your doctor may determine that your body can no longer tolerate the side effects and switch you to TASIGNA

 

In a clinical trial, TASIGNA was shown to be effective among patients who had taken GLEEVEC® (imatinib mesylate) first and then switched to TASIGNA.

 

At the time of the study in the mid-2000s, major cytogenetic response (MCyR) was the measured response. Of 321 patients with Ph+ CML, in chronic phase, 51% achieved MCyR and 37% achieved a complete cytogenetic response (CCyR) with TASIGNA. Later studies measured response using major molecular response (MMR) and DMR (MR4.5). 

 

Be sure to review information about the serious and most common side effects of TASIGNA. Learn more

 

Make your blood heard by speaking with your doctor

To have a productive conversation with your doctor about switching from your current medication to TASIGNA, download the Doctor Discussion Guide. You’ll find questions that you can discuss with your doctor to see if you may be resistant to, or intolerant of, your current treatment for Ph+ CML-CP.